Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups

Full details :
want listed ? contact
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Saturday, August 20, 2011

New TMAU medical paper by Monell/Denver

Individuals Reporting Idiopathic Malodor Production: Demographics and Incidence of Trimethylaminuria
Wise PM, Eades J, Tjoa S, Fennessey PV, Preti G.

Monell Chemical Senses Center, Philadelphia, Pa.

Individuals with the metabolic disorder trimethylaminuria may sporadically produce malodors despite good hygiene. The psychosocial impact of trimethylaminuria can be considerable. However, trimethylaminuria is difficult to diagnose without specialized tests, in part because odor production is diet-dependent and malodors may not be present during medical examinations. Thus, the prevalence and demographics of trimethylaminuria remain unclear.

We tested 353 patients who had unexplained (idiopathic) malodor production for trimethylaminuria using a standard choline challenge. We also collected basic demographic information.

Approximately one third of patients (118) tested positive for trimethylaminuria. Consistent with previous reports, women, particularly African American women, were significantly overrepresented among trimethylaminuria-positive patients. Of note, the same pattern was seen among trimethylaminuria-negative patients. Also consistent with previous reports, trimethylaminuria-positive women who were still menstruating tended to produce higher levels of trimethylamine within ±7 days of menses, although this trend was statistically marginal (P = .07).

If our patient sample is representative of patients with idiopathic malodor, demographic information (race and gender) may not be useful in a differential diagnosis of trimethylaminuria. However, undiagnosed cases of trimethylaminuria may be fairly common among patients with idiopathic malodor. If so, choline challenge testing should be indicated for all such patients because trimethylaminuria is responsive to dietary and other treatments. We speculate that testing also might reveal cases of trimethylaminuria among those diagnosed with certain psychologic disorders, including olfactory reference syndrome.

Opinion of blog post author on the abstract

This is the abstract of a new paper on trimethylaminuria (TMAU) published ahead of print of the full paper. It could be a paper unfinished from a while ago, since it includes Susan Tjoa as an author, who sadly passed away a few years ago now.

It sounds a very useful paper as evidence for the case of testing most people with a long-time suspected malodor problem, including those diagnosed with the recently defined psychiatric 'disorder' known as 'olfactory reference syndrome'.

Special points of interest
The number of people who 'failed' the test (about 1/3). This was probably under the 'Denver TMAU test reference ranges', which does not seem to regard TMA level alone as significant (and hence is very unlikely to find anyone positive for 'TMA substrate overload' (the most common type of TMAU2).

A large number of the positive cases were women and especially African American women. This seems to be a reflection of the community, although perhaps women are more likely to test. Nevertheless, women of African American descent seem to be over-represented in the community. Another point of interest relating to females is that although 'TMAU' is regarded as possibly being worse around menses, this proved so in the study but only marginally so.

They suggest it may be worthwhile testing those diagnosed with 'olfactory reference syndrome' for TMAU. This has been a MEBO Research suggestion for a while now. It would make an excellent study and possibly mark the end of 'ORS'.

They used a choline challange for the test. It would be interesting to see the test done using the 'TMAU carrier test' protocol, which involves taking 600mg TMA load. Normal people would still be able to process almost all of 600mg of TMA, but those with 'no reserve capacity' (probably all 'carriers') would likely show up along with 'sufferers'. It should also be noted that the test only applies to trimethylamine and not any other FMO3 substrate. Currently only trimethylamine is accepted by the few labs that do TMAU testing as being the only FMO3 substrate that causes an odor in people.


Post a Comment